C039P: Abciximab Biosimilar, Anti-human Glycoprotein IIb/IIIa Receptor Monoclonal Antibody

Catalog No.: C039P | **Product Name:** Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody

Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody. The research grade abciximab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C039P
Product Name	Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Humanized IgG1.
Source/Host	The anti-human Glycoprotein IIb/IIIa receptor monoclonal antibody abciximab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The research grade abciximab biosimilar specifically binds to the human Glycoprotein IIb and IIIa.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by abciximab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade abciximab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade abciximab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is Abciximab biosimilar research grade? Abciximab Biosimilar uses the same protein sequences as the therapeutic antibody abciximab. Abciximab, a glycoprotein IIb/IIIa receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor. While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug. Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.